Fixed Dose Combination (FDC) cemiplimab+fianlimab clinical trials

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

This study looks at a new combination of drugs, fianlimab and cemiplimab, for melanoma skin cancer. We want to see if this combination works better and is safe compared to cemiplimab alone for people with certain stages of melanoma that can be removed by surgery.